Picture of Abionyx Pharma SA logo

ABNX Abionyx Pharma SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

French and Benelux stocks-Factors to watch 21 Nov

21 Nov (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks.

ABIONYX PHARMA SA ABNX.PA:    Biotech company Abionyx Pharma announced an exclusive global strategic partnership with Sebia to transform sepsis diagnosis and validate new tests for early sepsis identification, with financial terms and milestones remaining confidential.

BOIRON SA BOI.PA:    Homeopathic drug manufacturer Boiron SA announced that Thierry Boiron is stepping down as Deputy Chief Executive Officer, effective December 31, 2025.

EIFFAGE SA FGR.PA:    French construction company Eiffage won a second contractfor the construction of infrastructure for the Madrid street circuit in Spain, valued at 68 million euros.

GENFIT SA GNFT.PA:    Biopharmaceutical company Genfit announced the effectiveness of the voluntary delisting of its American Depositary Shares from the Nasdaq Stock Market, with the delisting effective prior to the opening of trading on November 20, 2025.

IMERYS SA IMTP.PA:    Specialty minerals company Imerys successfully placed 600 million euros in senior unsecured bonds with a 7-year maturity and 4.00% fixed annual coupon, with settlement on November 21, 2025. The company also completed a cash tender offer for its 2027 bonds.

MAUNA KEA TECHNOLOGIES SA ALMKT.PA:    Medical device company Mauna Kea Technologies received NMPA regulatory approval in China for its next-generation Cellvizio Gen 3 platform and is evaluating options to commercialize the product in China.

ORANGE ORAN.PA: French telecom companies are exploring a wider bid for the assets of billionaire Patrick Drahi, reported the Financial Times.

SANOFI SASY.PA: Texas Attorney General Ken Paxton sued Bristol Myers Squibb BMY.N and Sanofi SASY.PA on Thursday, accusing the drugmakers of failing to disclose that Plavix, which is used to prevent blood clots, does not work effectively for many patients. In a joint statement, Bristol Myers and Sanofi said they will vigorously defend against Paxton's lawsuit.

TARKETT SA TKTT.PA:    Flooring and sports surface manufacturer Tarkett announced the reopening of the public buyout offer followed by a squeeze-out by Tarkett Participation on Tarkett shares for 10 trading days from November 24 to December 5, 2025, after the Paris court dismissed an annulment application against the AMF decision.

UNIVERSAL MUSIC GROUP N.V. UMG.AS:    Music company Universal Music Group, along with Universal Music Publishing Group, signed AI licensing deals with Klay, as did Sony Music Entertainment, Sony Music Publishing, Warner Music Group, and Warner Chappell Music, establishing terms for Klay to help evolve music experiences for fans leveraging AI potential.

Pan-European market data:

European Equities speed guide...................EUR/EQUITY

FTSE Eurotop 300 index...............................FTEU3

DJ STOXX index.......................................STOXX

Top 10 STOXX sectors............................PGL.STOXXS

Top 10 EUROSTOXX sectors.......................PGL.STOXXES

Top 10 Eurotop 300 sectors......................PGL.FTEU3S

Top 25 European pct gainers........................PG.PEUR

Top 25 European pct losers.........................PL.PEUR

Main stock markets:

Dow Jones................DJI Wall Street report ......N

Nikkei 225..............N225 Tokyo report.............T

FTSE 100................FTSE London report............L

Xetra DAX..............GDAXI Frankfurt items..........F

CAC-40..................FCHI Paris items.............PA

World Indices.....................................0#.INDEX

Reuters survey of world bourse outlook.........EQUITYPOLL1

European Asset Allocation........................EUR/ASSET

Reuters News at a glance:

Top News.............TOP/NEWS

Equities..............TOP/EQE

Main oil report...........O/R

Main currency report.....FRX/

(Jerome Terroy  jerome.terroy@thomsonreuters.com)

((Gdansk Newsroom: +48 58 769 66 00;Paris Equities: +33 1 49 49 54 52))

Recent news on Abionyx Pharma SA

See all news